Literature DB >> 25881609

Tongxinluo inhibits cyclooxygenase-2, inducible nitric oxide synthase, hypoxia-inducible factor-2α/vascular endothelial growth factor to antagonize injury in hypoxia-stimulated cardiac microvascular endothelial cells.

Yan-Ning Li, Xiu-Juan Wang, Bin Li, Kun Liu, Jin-Sheng Qi1, Bing-Hui Liu, Ye Tian.   

Abstract

BACKGROUND: Endothelial dysfunction is considered as the initiating process and pathological basis of cardiovascular disease. Cyclooxygenase-2 (COX-2) and prostacyclin synthase (PGIS), inducible nitric oxide synthase (iNOS) and endothelial NOS (eNOS) are key enzymes with opposing actions in inflammation and oxidative stress, which are believed to be the major driver of endothelial dysfunction. And in hypoxia (Hx), Hx-inducible factor (HIF)-1α and HIF-2α are predominantly induced to activate vascular endothelial growth factor (VEGF), resulting in abnormal proliferation. Whether and how Tongxinluo (TXL) modulates COX-2, PGIS, iNOS, eNOS, HIF-1α, HIF-2α, and VEGF in Hx-stimulated human cardiac microvascular endothelial cells (HCMECs) have not been clarified.
METHODS: HCMEC were treated with CoCl 2 to mimic Hx and the mRNA expressions of COX-2, PGIS, iNOS, eNOS, HIF-1α, HIF-2α, and VEGF were first confirmed, and then their mRNA expression and protein content as well as the cell pathological alterations were evaluated for TXL treatment with different concentrations. In addition, the effector molecular of inflammation prostaglandin E 2 (PGE 2 ) and the oxidative marker nitrotyrosine (NT) was adopted to reflect HCMEC injury.
RESULTS: Hx could induce time-dependent increase of COX-2, iNOS, HIF-2α, and VEGF in HCMEC. Based on the Hx-induced increase, TXL could mainly decrease COX-2, iNOS, HIF-2α, and VEGF in a concentration-dependent manner, with limited effect on the increase of PGIS and eNOS. Their protein contents verified the mRNA expression changes, which was consistent with the cell morphological alterations. Furthermore, high dose TXL could inhibit the Hx-induced increase of PGE 2 and NT contents, attenuating the inflammatory and oxidative injury.
CONCLUSIONS: TXL could inhibit inflammation-related COX-2, oxidative stress-related iNOS, and HIF-2α/VEGF to antagonize Hx-induced HCMEC injury.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25881609      PMCID: PMC4832955          DOI: 10.4103/0366-6999.155119

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


INTRODUCTION

Cardiovascular disease is the leading cause of deaths worldwide, especially atherosclerosis, and the subsequent vessel obliterations are the primary cause of ischemic disease (stroke, coronary heart disease).[12] Endothelial, especially microvascular endothelial dysfunction is believed to be the initiating process and pathological basis of cardiovascular disease.[345] Inflammation and oxidative stress have been widely accepted to be the key pathological process of cardiac microvascular endothelial cells.[67] Cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) are key enzymes in inflammation and oxidative stress, both of which are inducible enzymes and can be induced to mediate pathological damages.[89] When COX-2 is induced, excess prostaglandin E2 (PGE2) can be formed to mediate inflammation injury. While induced iNOS leads to superfluous peroxynitrite formation, which causes extensive protein tyrosine nitration, and nitrotyrosine (NT) is believed to be a marker of oxidative stress injury. In contrast to COX-2, prostacyclin synthase (PGIS) antagonize inflammation to play protective roles.[1011] And in contrary to inducible iNOS, constitutive expression of endothelial NOS (eNOS) is necessary for physiological vasodilatation.[12] Hypoxia (Hx)-inducible factors (HIFs) are transcription factors that respond to Hx. Mammalian HIFs function as heterodimers composed of either HIF-1α or HIF-2α bound to HIF-1β. HIF-1α appears to be ubiquitously expressed, whereas HIF-2α is more restricted to vascular endothelial cells.[1314] HIFs control a serial of genes to adapt to Hx, and vascular endothelial growth factor (VEGF), a major target gene of HIFs, promotes abnormal proliferation in Hx condition.[15] Although VEGF has the ability to promote angiogenesis, it may stimulate abnormal basement membrane thickening and smooth muscle cell proliferation, which result in vessel obliterations.[16] Besides VEGF, HIFs also contribute to the transactivation of COX-2 and iNOS, which leads to pathological processes.[1718] Tongxinluo (TXL) was registered in the State Food and Drug Administration of China for treatment of angina pectoris in 1996. It is extracted, concentrated, and freeze-dried from a group of herbal medicines, such as ginseng, radix paeoniae rubra, borneol, and spiny jujuba seed, which contains multiple active components that may be responsible for its antianginal effects.[192021] Our previous study revealed that ginsenoside, the main active component of TXL, could inhibit COX-2 and iNOS in L-methionine-induced rat vascular lesion.[8] Although TXL is reported to inhibit vascular inflammation, its effects on COX-2 and PGIS have not been explored.[22] Several studies revealed that TXL could modulate vascular endothelial function by inducing eNOS expression,[1923] however, what effect on iNOS is unknown. Moreover, TXL is found to have positive effects on myocardial HIF-1α and VEGF, but no effect on HIF-2α was found.[24] As the effect target of TXL is in microcirculation,[2526] the human cardiac microvascular endothelial cells (HCMECs) were adopted in this study to investigate whether TXL modulate COX-2, PGIS, iNOS, eNOS, HIF-1α, HIF-2α and VEGF expressions in Hx condition. After the cells were exposed to Hx and treated with TXL, the mRNA expressions of COX-2, PGIS, iNOS, eNOS, HIF-1α, HIF-2α, and VEGF were detected by real-time reverse transcription-polymerase chain reaction (RT-PCR), their protein contents was evaluated by Western blotting, the cell morphological alterations were observed under light microscope, PGE2 content was analyzed by ELISA and NT content was evaluated by immunofluorescence to reveal the antagonizing mechanism of TXL against the Hx-induced HCMEC injury.

METHODS

Cells and treatment

Human cardiac microvascular endothelial cell were purchased from ScienCell and cultured in Endothelial Cell Medium (ScienCell, USA). After the cells were treated with CoCl2 (dissolved in phosphate buffered saline (PBS), with final concentration 100 μmol/L),[27] the gene expressions of COX-2, PGIS, iNOS, eNOS, HIF-1α, HIF-2α, and VEGF were detected at different time to verify the optimal Hx stimulation time. Then the cells were divided into control (Con), Hx, Hx plus low dose TXL (300 μg/ml), Hx plus middle dose TXL (400 μg/ml) and Hx plus high dose TXL (500 μg/ml) groups.[22] The mRNA expressions of COX-2, PGIS, iNOS, eNOS, HIF-1α, HIF-2α, and VEGF were measured at 6 h treatment, and their protein contents were evaluated, the cell morphological alterations were observed under light microscope, NT distribution and content was evaluated and the supernatant was collected to analyze PGE2 content at 24 h treatment.

Real-time reverse transcription-polymerase chain reaction

The mRNA expressions of COX-2, PGIS, iNOS, eNOS, HIF-1α, HIF-2α, and VEGF were quantified by real-time RT-PCR. Total RNA was isolated using Trizol reagent (Takara, China) and reverse transcribed into cDNA using RevertAid First Strand cDNA synthesis Kit (Fermentas, USA), followed by real-time PCR amplification using specific primers [Table 1]. Actin primers were used as an internal standard.
Table 1

Primers used for real time PCR detection

ItemsPrimers (5’−3’)Annealing temperature (°C)Product size (bp)
COX-2
 SenseCTTTGCCCAGCACTTCACGCATCAG65269
 Anti-senseCCTGCCCCACAGCAAACCGTAGATG
PGIS
 SenseGAGACGGAGTTTCACGCTTATTGC60228
 Anti-senseAGGCAAATCACGAGGTCAGGAG
iNOS
 SenseCCAGCCTCAAGTCTTATTTCCTC55177
 Anti-senseGCAAGTTCCATCTTTCACCCAC
eNOS
 SenseACGAGACGCTGGTGCTGGTGGTAAC62274
 Anti-senseGAGCCGAGCCCGAACACACAGAAC
HIF-1
 SenseCCTGCTTGGTGCTGATTTGTG55265
 Anti-senseCTGTACTGTCCTGTGGTGACTTGTC
HIF-2
 SenseGAAATGGAATCCTGCTCACAAAATC60287
 Anti-senseTGAAAGACCATCCGAGTCACATAGC
VEGF
 SenseTAGACACACCCACCCACATACATAC55173
 Anti-senseCCCAACTCAAGTCCACAGCAG
β-actin
 SenseCTCCATCCTGGCCTCGCTGT60268
 Anti-senseGCTGTCACCTTCACCGTTCC

PCR: Polymerase chain reaction.

Primers used for real time PCR detection PCR: Polymerase chain reaction.

Western blotting

The protein contents of COX-2, PGIS, iNOS, eNOS, HIF-1α, HIF-2α, and VEGF were detected by Western blotting, with the protocol previously described.[28] Briefly, cells were lysed in lysis buffer (RIPA, Solarbio, China) to extract whole proteins. Protein content was determined by NanoDrop-1000 (Thermo Scientific, USA). Then samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to the polyvinylidene fluoride membrane (Millipore, USA). After the membrane was blocked with milk, anti-COX-2 (Santa Cruz, USA), anti-PGIS (Santa Cruz), anti-iNOS (Santa Cruz), anti-eNOS (Santa Cruz), anti-HIF-1α (Sangon Biotech), anti-HIF-2α (Sangon Biotech), anti-VEGF antibodies (Sangon Biotech, China) or anti-beta actin (Sangon Biotech) were used. Band intensity was quantified and calculated.

ELISA

After treated, the culture medium was collected to analyze PGE2 by ELISA (Jiancheng, Nanjing, China). Standards and samples were added to wells of the plate and incubated for 1 h. After the wells were washed with the ELISA wash buffer, the conjugated antibody was added and incubated for 1 h. Then the wells were again washed with the ELISA wash buffer. The substrate was added in the wells and incubated for 15 min. Then the stop solution was added, and absorption was measured with an ELISA reader at 450 nm. The tests were carried out in duplicate.

Immunofluorescence

The distribution and contents of NT were measured by immunofluorescence with the procedure previously reported.[28] After incubated with the anti-NT antibody (Abcam, UK) and then the secondary antibody (fluorescein isothiocyanate, Zhongshan, China), cells were observed under a fluorescence microscope (Olympus IX51). To get exact results, controls (PBS instead of the first antibody or the second antibody) were designed.

Statistical analysis

Statistical analysis of the data was performed using SPSS software (Chicago, IL, USA) and presented as means ± standard deviation. The experiments were repeated twice, and comparisons between two groups were performed using Student's t-test. P < 0.05 were considered statistically significant.

RESULTS

Hypoxia-induced time-dependent changes of gene expressions

After the cells were stimulated by Hx for different time, the gene expressions of COX-2, PGIS, iNOS, eNOS, HIF-1α, HIF-2α, and VEGF were detected by real-time RT-PCR [Figure 1]. The inflammation-related COX-2 increased at 4 h, 6 h and 8 h, while the protective PGIS decreased at 8 h [Figure 1a]. The oxidative stress-related iNOS elevated sharply at 4 h, 6 h and 8 h, with no significant changes of eNOS [Figure 1b]. The Hx-induced HIF-1α increased at 4 h and 6 h, but HIF-2α and VEGF rose obviously at 4 h, 6 h and 8 h [Figure 1c]. The results indicated that Hx mainly triggered COX-2, iNOS, and HIF-2α/VEGF in a time-dependent manner in HCMEC.
Figure 1

Hypoxia (Hx) induced time-dependent changes of gene expressions. The gene expressions were detected by real-time reverse transcription-polymerase chain reaction. (a) Hx induced increase of cyclooxygenase-2 and decrease of prostacyclin synthase; (b) Hx induced increase of inducible nitric oxide synthase; (c) Hx induced increase of Hx-inducible factor (HIF)-1α, HIF-2α and vascular endothelial growth factor *P < 0.05, compared with 0 h group. The data were repeated twice and represented as mean ± standard division.

Hypoxia (Hx) induced time-dependent changes of gene expressions. The gene expressions were detected by real-time reverse transcription-polymerase chain reaction. (a) Hx induced increase of cyclooxygenase-2 and decrease of prostacyclin synthase; (b) Hx induced increase of inducible nitric oxide synthase; (c) Hx induced increase of Hx-inducible factor (HIF)-1α, HIF-2α and vascular endothelial growth factor *P < 0.05, compared with 0 h group. The data were repeated twice and represented as mean ± standard division.

Tongxinluo modulated the hypoxia-induced gene expressions

The cells were treated with low-, middle- and high-dose TXL for 6 h, and then the gene expressions of COX-2, PGIS, iNOS, eNOS, HIF-1α, HIF-2α, and VEGF were detected by real-time RT-PCR [Figure 2]. At first, it was found that middle dose TXL had no obvious effect on the gene expressions. The Hx-induced COX-2 and iNOS could be reduced by middle- and high-dose-TXL, and PGIS and eNOS increased significantly only in high-dose TXL group [Figure 2a and b]. The Hx-induced HIF-2α and VEGF were also decreased in the middle- and high-dose TXL groups, although HIF-1α showed no significant changes among groups [Figure 2c]. The results manifested that TXL, especially in high dose, could suppress Hx-induced COX-2, iNOS, and HIF-2α/VEGF to exhibit protective roles in HCMEC.
Figure 2

Tongxinluo (TXL) affected the hypoxia-induced gene expression changes. The gene expressions were detected by real-time reverse transcription-polymerase chain reaction. (a) TXL decreased the hypoxia-induced cyclooxygenase-2, with increase of prostacyclin synthase; (b) TXL decreased the hypoxia-induced inducible nitric oxide synthase, with increase of endothelial NOS; (c) TXL decreased the hypoxia-induced factor-2α and vascular endothelial growth factor *P < 0.05, compared with control (Con) group; †P < 0.05, compared with hypoxia group. The data were repeated twice and represented as mean ± standard division. LT: Low dose TXL; MT: Middle dose TXL; HT: High-dose TXL.

Tongxinluo (TXL) affected the hypoxia-induced gene expression changes. The gene expressions were detected by real-time reverse transcription-polymerase chain reaction. (a) TXL decreased the hypoxia-induced cyclooxygenase-2, with increase of prostacyclin synthase; (b) TXL decreased the hypoxia-induced inducible nitric oxide synthase, with increase of endothelial NOS; (c) TXL decreased the hypoxia-induced factor-2α and vascular endothelial growth factor *P < 0.05, compared with control (Con) group; †P < 0.05, compared with hypoxia group. The data were repeated twice and represented as mean ± standard division. LT: Low dose TXL; MT: Middle dose TXL; HT: High-dose TXL.

Tongxinluo adjusted the hypoxia-induced protein contents

The cells were treated with low-, middle- and high-dose TXL for 24 h, and then the protein contents of COX-2, PGIS, iNOS, eNOS, HIF-1α, HIF-2α, and VEGF were detected by Western blotting [Figure 3a]. The Hx-induced COX-2 and iNOS could be reduced by TXL in a concentration-dependent manner, but PGIS merely increased significantly in high dose TXL group and difference of eNOS was hardly seen among groups [Figure 3b and c]. The Hx-induced HIF-2α decreased by TXL in a concentration-dependent manner, however, HIF-1α and VEGF were reduced significantly only in high-dose TXL group [Figure 3d]. The protein content changes were in accordance with that of their mRNA expressions, confirming the effects of TXL on COX-2, iNOS, and HIF-2α/VEGF in HCMEC.
Figure 3

Effects of tongxinluo (TXL) on the hypoxia-induced protein content changes. (a) The protein contents of cyclooxygenase-2 (COX-2), prostacyclin synthase (PGIS), inducible nitric oxide synthase (iNOS), endothelial NOS, hypoxia-inducible factor (HIF)-1α, HIF-2α, and vascular endothelial growth factor (VEGF) were detected by Western blotting; (b) TXL decreased the hypoxia-induced COX-2, with increase of PGIS; (c) TXL decreased the hypoxia-induced iNOS; (d) TXL decreased the hypoxia-induced HIF-1α, HIF-2α, and VEGF. *P < 0.05 or †P < 0.01, compared with control (Con) group; ‡P < 0.05 or §P < 0.01, compared with hypoxia group. The data were repeated twice and represented as mean ± standard division. LT: Low dose TXL; MT: Middle dose TXL; HT: High-dose TXL.

Effects of tongxinluo (TXL) on the hypoxia-induced protein content changes. (a) The protein contents of cyclooxygenase-2 (COX-2), prostacyclin synthase (PGIS), inducible nitric oxide synthase (iNOS), endothelial NOS, hypoxia-inducible factor (HIF)-1α, HIF-2α, and vascular endothelial growth factor (VEGF) were detected by Western blotting; (b) TXL decreased the hypoxia-induced COX-2, with increase of PGIS; (c) TXL decreased the hypoxia-induced iNOS; (d) TXL decreased the hypoxia-induced HIF-1α, HIF-2α, and VEGF. *P < 0.05 or †P < 0.01, compared with control (Con) group; ‡P < 0.05 or §P < 0.01, compared with hypoxia group. The data were repeated twice and represented as mean ± standard division. LT: Low dose TXL; MT: Middle dose TXL; HT: High-dose TXL.

Tongxinluo attenuated the hypoxia-induced human cardiac microvascular endothelial cell injury

After the cells were treated with low-, middle-, and high-dose TXL for 24 h, their morphological alterations were observed under light microscope [Figure 4a]. As illustrated, in contrast to control group, the cells shrank, turned round and seem to die in Hx group. However, for TXL treatments, the morphological injury was attenuated gradually with its concentration ascending. Moreover, PGE2 increased significantly in Hx group, and high dose TXL could inhibit the Hx-induced increase [Figure 4b]. Meanwhile, the Hx-induced accumulation of NT content could be attenuated obviously by high dose TXL treatment [Figure 4c]. The results demonstrated that TXL could attenuate the Hx-induced HCMEC injury.
Figure 4

Tongxinluo (TXL) attenuated the hypoxia (Hx)-induced injury (×400). (a) Compared to control (Con) group, the cells shrank, turned round and seem to die in Hx group, which could be obviously attenuated by TXL treatments; (b) Prostaglandin E2 content increased in Hx group, and significantly decreased in Hx plus high dose TXL (HT) group, *P < 0.05, compared with control (Con) group; †P < 0.05, compared with hypoxia group; (c) Nitrotyrosine content dramatically increased in Hx group, and was obviously inhibited in Hx plus HT group. LT: Low dose TXL; MT: Middle dose TXL.

Tongxinluo (TXL) attenuated the hypoxia (Hx)-induced injury (×400). (a) Compared to control (Con) group, the cells shrank, turned round and seem to die in Hx group, which could be obviously attenuated by TXL treatments; (b) Prostaglandin E2 content increased in Hx group, and significantly decreased in Hx plus high dose TXL (HT) group, *P < 0.05, compared with control (Con) group; †P < 0.05, compared with hypoxia group; (c) Nitrotyrosine content dramatically increased in Hx group, and was obviously inhibited in Hx plus HT group. LT: Low dose TXL; MT: Middle dose TXL.

DISCUSSION

Endothelial dysfunction is considered as the initiating process and pathological basis of cardiovascular disease. TXL could effectively improve the cardiac microcirculation to antagonize Hx, however, the underlying mechanism is still not fully clarified. Inflammation, oxidative stress, and HIFs make a vicious cycle to drive the pathological process of endothelial dysfunction. Whether and how TXL affects COX-2, PGIS, iNOS, eNOS, HIF-1α, HIF-2α, and VEGF in Hx-stimulated HCMEC is unknown. In this study, it was found that TXL could mainly inhibit the Hx-induced COX-2, iNOS, HIF-2α/VEGF in a concentration-dependent manner, with attenuation of cell morphological injury, PGE2, and NT contents. The results manifested that TXL modulated inflammation-related COX-2, oxidative stress-related iNOS, and HIF-2α/VEGF to antagonize the Hx-induced HCMEC injury. The immense endothelium surface area in microcirculation makes this region more vulnerable to injury. Since the endothelial cell layer constitutes the primary barrier and co-ordinates the overlying smooth muscle cell layer, microvascular endothelial dysfunction is believed to be the initiating process and pathological basis of cardiovascular disease.[34529] In this study, HCMEC was adopted to investigate the Hx-induced heart microvascular endothelial cell injury. Inflammation and oxidative stress have been widely believed to be the key pathological process of cardiac microvascular endothelial cells. COX-2 and PGIS are enzymes with opposing actions in inflammation, and in contrary to iNOS, eNOS plays constitutive roles in physiological vasodilatation.[89101112] The mutual promotion COX-2 and iNOS may contribute to vascular disease, which has also been proved by our previous study.[30] Meanwhile, HIF-1α and HIF-2α are induced by Hx, which can drive VEGF expression, resulting in abnormal proliferation.[1314] Besides, VEGF, COX-2, and iNOS are other target genes of HIFs in Hx. Whether these factors are involved in the Hx-induced HCMEC pathological process is unknown. At first, the mRNA expressions of COX-2, PGIS, iNOS, eNOS, HIF-1α, HIF-2α, and VEGF in Hx-stimulated HCMEC were detected. The results found that Hx could dramatically induce COX-2, iNOS, HIF-2α and VEGF in a time-dependent manner, validating the involvement of inflammation, oxidative stress and HIFs/VEGF in the Hx-induced HCMEC dysfunction. Tongxinluo has satisfactory beneficial effects on cardiovascular disease, particularly in the modulation of microcirculation.[1920212526] About the mechanism of TXL, several researchers focus on the regulation of eNOS, and still others explore its effect on micro RNAs.[2231] Although inflammation, oxidative stress and HIFs/VEGF have been considered as the key pathological process in Hx stimulation, whether and how TXL affects the inflammation-related COX-2, oxidative stress-related iNOS, and HIF-2α/VEGF have not been explored. Therefore, based on the Hx-induced expression of COX-2, iNOS, HIF-2α, and VEGF, the effects of TXL were investigated in Hx-stimulated HCMEC. In this study, it first revealed that TXL could inhibit the mRNA expressions of COX-2, iNOS, HIF-2α and VEGF in a concentration-dependent manner, with up-regulation of PGIS and eNOS. Then their protein contents showed that TXL could concentration-dependently suppress COX-2, iNOS, HIF-2α, and VEGF, with slight up-regulation of PGIS and down-regulation of HIF-1α. These data manifested that TXL mainly inhibited the Hx-induced COX-2, iNOS, HIF-2α/VEGF in HCMEC. Furthermore, the morphological alterations illustrated that Hx brought the conspicuous injury to HCMEC, and TXL could obviously attenuate the pathological alterations with its concentration ascending. As known, COX-2 synthesizes PGE2 to mediate inflammation and iNOS causes extensive oxidative stress injury, which can be reflected by NT content. And besides VEGF, HIFs also exhibit Hx-induced effects via iNOS. In this study, it was found that PGE2 and NT contents increased in Hx group, reflecting the Hx-induced HCMEC injury, and high-dose TXL could obviously reduce the induced PGE2 and NT contents. The results demonstrated that TXL could antagonize Hx-induced HCMEC morphological, inflammatory, and oxidative stress injury. In conclusion, hypoxia triggered inflammation-related COX-2, oxidative stress-related iNOS, and HIF-2α/VEGF to cause HCMEC injury, and TXL treatment could inhibit COX-2, iNOS, HIF-2α/VEGF to antagonize the Hx-induced injury.
  31 in total

1.  Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes.

Authors:  Nicolas Skuli; Amar J Majmundar; Bryan L Krock; Rickson C Mesquita; Lijoy K Mathew; Zachary L Quinn; Anja Runge; Liping Liu; Meeri N Kim; Jiaming Liang; Steven Schenkel; Arjun G Yodh; Brian Keith; M Celeste Simon
Journal:  J Clin Invest       Date:  2012-03-19       Impact factor: 14.808

2.  Hypoxia upregulates PGI-synthase and increases PGI₂ release in human vascular cells exposed to inflammatory stimuli.

Authors:  Mercedes Camacho; Cristina Rodríguez; Anna Guadall; Sonia Alcolea; Mar Orriols; José-Román Escudero; José Martínez-González; Luis Vila
Journal:  J Lipid Res       Date:  2011-02-04       Impact factor: 5.922

3.  Chinese medicine Tongxinluo modulates vascular endothelial function by inducing eNOS expression via the PI-3K/Akt/HIF-dependent signaling pathway.

Authors:  Jun Qing Liang; Kun Wu; Zhen Hua Jia; Chang Liu; Jin Ding; Shan Na Huang; Pei Pei Yin; Xiang Chun Wu; Cong Wei; Yi Ling Wu; Hong Yang Wang
Journal:  J Ethnopharmacol       Date:  2010-10-20       Impact factor: 4.360

4.  Peroxynitrite-induced nitration of cyclooxygenase-2 and inducible nitric oxide synthase promotes their binding in diabetic angiopathy.

Authors:  Yanning Li; Jinsheng Qi; Kun Liu; Bin Li; Hui Wang; Jinhai Jia
Journal:  Mol Med       Date:  2010-06-30       Impact factor: 6.354

5.  Interaction between COX-2 and iNOS aggravates vascular lesion and antagonistic effect of ginsenoside.

Authors:  Yan-Ning Li; Yi-Ling Wu; Zhen-Hua Jia; Jin-Sheng Qi
Journal:  J Ethnopharmacol       Date:  2008-07-25       Impact factor: 4.360

6.  Protein kinase A-mediated cardioprotection of Tongxinluo relates to the inhibition of myocardial inflammation, apoptosis, and edema in reperfused swine hearts.

Authors:  Xiang-dong Li; Yue-jin Yang; Yu-tong Cheng; Ke-fei Dou; Yi Tian; Xian-min Meng
Journal:  Chin Med J (Engl)       Date:  2013       Impact factor: 2.628

Review 7.  Hypoxia and ischemia-reperfusion: a BiK contribution?

Authors:  Jean-Yves Tano; Maik Gollasch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-07-11       Impact factor: 4.733

8.  Endothelial cell HIF-1α and HIF-2α differentially regulate metastatic success.

Authors:  Cristina Branco-Price; Na Zhang; Moritz Schnelle; Colin Evans; Dörthe M Katschinski; Debbie Liao; Lesley Ellies; Randall S Johnson
Journal:  Cancer Cell       Date:  2012-01-17       Impact factor: 31.743

9.  Tongxinluo Improves Cardiac Function and Ameliorates Ventricular Remodeling in Mice Model of Myocardial Infarction through Enhancing Angiogenesis.

Authors:  Wen-Wu Bai; Yi-Fan Xing; Bo Wang; Xiao-Ting Lu; Ying-Bin Wang; Yuan-Yuan Sun; Xiao-Qiong Liu; Tao Guo; Yu-Xia Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-27       Impact factor: 2.629

10.  Tongxinluo protects against pressure overload-induced heart failure in mice involving VEGF/Akt/eNOS pathway activation.

Authors:  Bo Wang; Qing Yang; Wen-wu Bai; Yi-fan Xing; Xiao-ting Lu; Yuan-yuan Sun; Yu-xia Zhao
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

View more
  6 in total

1.  Tea polyphenols protect against ischemia/reperfusion-induced liver injury in mice through anti-oxidative and anti-apoptotic properties.

Authors:  Jin Tao; Xinhong Shen; Yonghong Ai; Xiaojing Han
Journal:  Exp Ther Med       Date:  2016-10-11       Impact factor: 2.447

2.  Tongxinluo Reverses the Hypoxia-suppressed Claudin-9 in Cardiac Microvascular Endothelial Cells.

Authors:  Kun Liu; Xiu-Juan Wang; Yan-Ning Li; Bin Li; Jin-Sheng Qi; Jing Zhang; Yu Wang
Journal:  Chin Med J (Engl)       Date:  2016-02-20       Impact factor: 2.628

3.  Potential Effectiveness of Chinese Patent Medicine Tongxinluo Capsule for Secondary Prevention After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Min Li; Chengyu Li; Shiqi Chen; Yang Sun; Jiayuan Hu; Chen Zhao; Ruijin Qiu; Xiaoyu Zhang; Qin Zhang; Guihua Tian; Hongcai Shang
Journal:  Front Pharmacol       Date:  2018-08-03       Impact factor: 5.810

Review 4.  Molecular basis of acute coronary syndrome.

Authors:  Natalya Balashkevich; Maxut Kazymov; Marat Syzdykbayev; Aima Adylova
Journal:  J Res Med Sci       Date:  2022-05-30       Impact factor: 1.985

5.  Vitamin D stimulates miR-26b-5p to inhibit placental COX-2 expression in preeclampsia.

Authors:  Yang Cao; Xiaotong Jia; Yujia Huang; Jiao Wang; Chunmei Lu; Xiaolei Yuan; Jie Xu; Hui Zhu
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

6.  A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Study of the Effects of Tongxinluo Capsules in Acute Coronary Syndrome Patients with High On-Treatment Platelet Reactivity.

Authors:  Lei Zhang; Yi Li; Bai-Song Yang; Lu Li; Xiao-Zeng Wang; Mei-Ling Ge; Quan-Min Jing; Ying-Yan Ma; Geng Wang; Hai-Wei Liu; Xin Zhao; Bin Wang; Kai Xu; Ya-Ling Han
Journal:  Chin Med J (Engl)       Date:  2018-03-05       Impact factor: 2.628

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.